Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1661998 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $15.56Day +6.28%Mkt cap $248MP/E (FY) 6.0×1Y +651.7%Off 52W high −34.0%Vol (1Y) 175.6%
Daily closing price, split-adjusted to the current basis; 2.3y shown of 585 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.3% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+5.86% |
| Top-10 13F concentration88.5% |
| Next report (est.)2026-08-04 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)6.0× |
| Sales (TTM)$0 |
| Earnings (TTM)$33.2M |
| ROE125.1% |
| Net margin55.5% |
| Sales growth 3Y155.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+368.7% |
| 1Y+651.7% |
| Since incept. (ann.)−2.8% |
Total return through 2026-07-30 · series begins 2024-03-26. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)175.6% |
| Ann. volatility (3Y)167.5% |
| Sharpe (1Y)1.83 |
| Sharpe (3Y)0.75 |
| Max drawdown (1Y)−51.1% |
| Max drawdown (3Y)−97.3% |
| Beta (3Y vs SPY)−0.36 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 2.3M | $14M | 15.40% | +0.0% |
| Atlas Venture Life Science Advisors, LLC | 2.1M | $13M | 14.30% | +0.0% |
| Opaleye Management Inc. | 1.3M | $8M | 8.59% | +488.8% |
| Carlyle Group Inc. | 1.1M | $7M | 7.54% | +0.0% |
| ARCH Venture Management, LLC | 320,482 | $2M | 2.19% | +0.0% |
| ACORN CAPITAL ADVISORS, LLC | 315,052 | $2M | 2.15% | −36.1% |
| VANGUARD CAPITAL MANAGEMENT LLC | 306,401 | $2M | 2.09% | new |
| MACKENZIE FINANCIAL CORP | 246,304 | $2M | 1.68% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$0.54 | — | — | — |
| 2025-09-30 | 2025-11-13 | −$0.60 | — | — | — |
| 2025-06-30 | 2025-08-06 | −$0.78 | — | — | — |
| 2025-03-31 | 2025-05-08 | −$0.90 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-04 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
